Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter . …A U.S. Food and Drug Administration advisory panel voted 9-to-3 against effectiveness data for a Capricor Therapeutics treatment for Duchenne muscular dystrophy, STAT tells us. Last year, the agency declined to approve ​the therapy ⁠and sought additional data after saying the treatment did not meet efficacy requirements. AdvertisementThe U.S. Federal Trade Commission sued Hims & Hers, continuing a pattern of action against the business practices and use of consumer health data by digital health companies, STAT notes.